Neurizon Therapeutics
June 16, 2025
Company Presentation
Orphan and Rare Disease
Neurizon is a publicly listed Australian company (ASX:NUZ) that is developing NUZ-001 for the treatment of neurodegenerative diseases. NUZ-001 is a small molecule mTOR inhibitor that activates autophagy in neuronal cells, offering a potential new treatment for a range of neurodegenerative diseases. Neurizon's lead clinical program is in Amyotrophic Lateral Scelrosis (ALS) with pre-clinical programs in Alzheimer's and Parkinson's Disease. NUZ-001 has been accepted onto the prestigious HEALEY ALS Platform at Massachussets General Hospital for a Phase II/III study in ALS patients, scheduled to commence in 2025.
Company HQ City:
South Melbourne
Company HQ State:
Victoria
Company HQ Country:
Australia
Year Founded:
2024
Lead Product in Development:
NUZ-001
CEO
Dr. Michael Thurn
Year Founded
2024
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
Exchange
Australian Stock Exchange
Ticker
ASX:NUZ
When you expect your next catalyst update?
Top-line read out from the HEALEY ALS Platform trial
What is your next catalyst (value inflection) update?
July 2026
Website
www.neurizon.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}